Home / Brand archive
105 reported ongoing
116 records in this archive. Latest source date Jul 23, 2026.
FDA enforcement status can lag behind the recall lifecycle. An empty search or a reported termination is not a personal product-safety determination.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Class IIReported ongoing
Distribution: Nationwide in the USA
cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Class IIReported ongoing
Distribution: Nationwide in the USA
cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Class IIReported ongoing
Distribution: Nationwide in the USA
Defective Container: Firm received complaints of broken tube at the seal.
Class IIIReported ongoing
Distribution: Nationwide in the US.
Defective Delivery System: The dip tube is clogged causing the spray not to work.
Class IIReported ongoing
Distribution: Nationwide in the USA
Subpotent Drug
Class IIReported completed
Distribution: Product was distributed nationwide within the United States.
Failed Dissolution Specifications: below specification results
Class IIReported ongoing
Distribution: Nationwide USA
CGMP Deviations
Class IIReported ongoing
Distribution: U.S. Nationwide
Failed Dissolution Specifications: results below specifications
Class IIReported ongoing
Distribution: USA Nationwide
Failed Dissolution Specifications
Class IReported ongoing
Distribution: Nationwide
Failed Dissolution Specifications
Class IReported ongoing
Distribution: Nationwide
CGMP Deviations
Class IIReported ongoing
Distribution: Nationwide
CGMP Deviations
Class IIReported ongoing
Distribution: Nationwide
CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class IIReported ongoing
Distribution: US Nationwide.
CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class IIReported ongoing
Distribution: US Nationwide.
CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class IIReported ongoing
Distribution: US Nationwide.
CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Class IIReported ongoing
Distribution: US Nationwide.
Failed Dissolution Specifications
Class IIReported ongoing
Distribution: Nationwide in the USA.
Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.
Class IIReported ongoing
Distribution: Nationwide in the US
Failed Excipient Specifications: OOS for assay of Isopropyl Alcohol
Class IIReported terminated
Distribution: USA Nationwide
These examples come from this result page and are not a ranking of every recall reason.
This archive contains 116 records, including 105 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.